GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Net Margin %

Medicenna Therapeutics (TSX:MDNA) Net Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Medicenna Therapeutics's Net Income for the three months ended in Dec. 2023 was C$-4.98 Mil. Medicenna Therapeutics's Revenue for the three months ended in Dec. 2023 was C$0.00 Mil. Therefore, Medicenna Therapeutics's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Medicenna Therapeutics's Net Margin % or its related term are showing as below:


TSX:MDNA's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -154.15
* Ranked among companies with meaningful Net Margin % only.

Medicenna Therapeutics Net Margin % Historical Data

The historical data trend for Medicenna Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Net Margin % Chart

Medicenna Therapeutics Annual Data
Trend Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net Margin %
Get a 7-Day Free Trial Premium Member Only - - - - -

Medicenna Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Medicenna Therapeutics's Net Margin %

For the Biotechnology subindustry, Medicenna Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicenna Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's Net Margin % falls into.



Medicenna Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Medicenna Therapeutics's Net Margin for the fiscal year that ended in Mar. 2023 is calculated as

Net Margin=Net Income (A: Mar. 2023 )/Revenue (A: Mar. 2023 )
=-10.048/0
= %

Medicenna Therapeutics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-4.977/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicenna Therapeutics  (TSX:MDNA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Medicenna Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicenna Therapeutics (TSX:MDNA) Business Description

Traded in Other Exchanges
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Executives
Albert George Beraldo Director
Chandra Panchal Director

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines